Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?

被引：29

作者：

Alsoud, Dahham ^{[1
]}

Vermeire, Severine ^{[1
,2
]}

Verstockt, Bram ^{[1
,2
]}

机构：

[1] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Translat Res Gastrointestinal Disorders TARGID IB, Leuven, Belgium

[2] Katholieke Univ Leuven, Dept Gastroenterol & Hepatol, Univ Hosp Leuven, Leuven, Belgium

来源：

CURRENT OPINION IN PHARMACOLOGY | 2020年 / 55卷

关键词：

CROHNS-DISEASE; MAINTENANCE THERAPY; ULCERATIVE-COLITIS; INDUCTION THERAPY; TROUGH LEVELS; SUBCUTANEOUS USTEKINUMAB; CLINICAL PHARMACOKINETICS; DOSE INTENSIFICATION; IBD PATIENTS; INFLIXIMAB;

D O I：

10.1016/j.coph.2020.09.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Therapeutic drug monitoring (TDM) plays a vital role in implementing precision medicine in inflammatory bowel disease (IBD), and may contribute to increased effectiveness, lower rates of drug toxicity and cost savings. While expert panels advocate the use of reactive TDM for anti-tumor necrosis factor (anti-TNF) agents, TDM is not yet widely recommended for non-anti TNF biologicals. We provide an overview of the observational evidence of the value of TDM in case of vedolizumab and ustekinumab. We also shed light on obstacles that need to be addressed before establishing wide acceptance of TDM in the field of IBD. In this respect, new analytical techniques and modelling approaches are being developed to further optimize efficacy of TDM and to facilitate general acceptance of this tool in personalizing IBD management.

引用

页码：17 / 30

页数：14

共 94 条

[1] Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis [J].

Adedokun, Omoniyi J. ;

Xu, Zhenhua ;

Marano, Colleen ;

O'Brien, Chris ;

Szapary, Philippe ;

Zhang, Hongyan ;

Johanns, Jewel ;

Leong, Rupert W. ;

Hisamatsu, Tadakazu ;

Van Assche, Gert ;

Danese, Silvio ;

Abreu, Maria T. ;

Sands, Bruce E. ;

Sandborn, William J. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (10) :2244-+

[2] Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease [J].

Adedokun, Omoniyi J. ;

Xu, Zhenhua ;

Gasink, Christopher ;

Jacobstein, Douglas ;

Szapary, Philippe ;

Johanns, Jewel ;

Gao, Long-Long ;

Davis, Hugh M. ;

Hanauer, Stephen B. ;

Feagan, Brian G. ;

Ghosh, Subrata ;

Sandborn, William J. .

GASTROENTEROLOGY, 2018, 154 (06) :1660-1671

[3] Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis [J].

Adedokun, Omoniyi J. ;

Sandborn, William J. ;

Feagan, Brian G. ;

Rutgeerts, Paul ;

Xu, Zhenhua ;

Marano, Colleen W. ;

Johanns, Jewel ;

Zhou, Honghui ;

Davis, Hugh M. ;

Cornillie, Freddy ;

Reinisch, Walter .

GASTROENTEROLOGY, 2014, 147 (06) :1296-+

[4] Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays [J].

Afonso, J. ;

Lopes, S. ;

Goncalves, R. ;

Caldeira, P. ;

Lago, P. ;

Tavares de Sousa, H. ;

Ramos, J. ;

Goncalves, A. R. ;

Ministro, P. ;

Rosa, I. ;

Vieira, A. I. ;

Dias, C. C. ;

Magro, F. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (07) :684-692

[5] Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease [J].

Al-Bawardy, Badr ;

Ramos, Guilherme Piovezani ;

Willrich, Maria Alice V. ;

Jenkins, Sarah M. ;

Park, Sang Hyoung ;

Aniwan, Satimai ;

Schoenoff, Shayla A. ;

Bruining, David H. ;

Papadakis, Konstantinos A. ;

Raffals, Laura ;

Tremaine, William J. ;

Loftus, Edward V. .

INFLAMMATORY BOWEL DISEASES, 2019, 25 (03) :580-586

[6] Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease [J].

Battat, Robert ;

Kopylov, Uri ;

Bessissow, Talat ;

Bitton, Alain ;

Cohen, Albert ;

Jain, Anjali ;

Martel, Myriam ;

Seidman, Ernest ;

Afif, Waqqas .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (09) :1427-+

[7]

Berends S, 2019, J CROHNS COLITIS, V13, pS414

[8] Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation [J].

Berends, Sophie E. ;

D'Haens, Geert R. A. M. ;

Schaap, Tiny ;

de Vries, Annick ;

Rispens, Theo ;

Bloem, Karien ;

Mathot, Ron A. A. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) :1544-1551

[9]

BG Feagan, 2014, CURR GASTROENTEROL R, P16

[10] Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations [J].

Bian, Sumin ;

Van den Berghe, Nathalie ;

Vandersmissen, Liesbeth ;

Tops, Sophie ;

Vermeire, Severine ;

Ferrante, Marc ;

Gils, Ann ;

Thomas, Debby .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2020, 185

← 1 2 3 4 5 6 7 8 9 10 →